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ABSTRACT 
For many years it has been perceived wisdom that HRT for women with a 
uterus should include a progestin to prevent the proliferative effects of 
estrogen on the endometrium and endometrial cancer. But, with the reports 
from the Women’s Health Initiative and Million Women Study indicating that 
such regimens are associated with an increased risk of breast cancer, whereas 
unopposed estrogen may not increase this risk, or even reduce it,  it is 
pertinent to reassess the merits of adding a progestin. In addition, the 
suggestion from the WHI that the effects of estrogen and progestins are a 
‘class effect’ are clearly inaccurate, as there is particular evidence from the 
French E3N cohort studies of differential effects of progestins with 
progesterone and dydrogesterone additions showing no increase in risk of 
breast cancer. The data are presented but an answer to the posed question 
remains unclear and as usual dependent on the circumstances and views of 






It has been widely advocated that Progestins be added to hormone 
replacement therapy (HRT) regimens since the 1970’s when the 
evidence that unopposed estrogen caused endometrial hyperplasia 
and cancer was highlighted by several reports from the west coast of 
USA1-3. Initially this was by sequential addition of 7-14 days in each 
month, with the production of a withdrawal bleed and endometrial 
shedding and more recently the continuous combined regimens have 
been promoted, which keep the endometrium atrophic and reduce 
the incidence of unacceptable bleeding. However, it is the progestin 
element of HRT which causes most of the mild side-effects, such as 
premenstrual-type symptoms, but more importantly seems to be the 
main factor that increases the risk of breast cancer, as shown in the 
Women’s Health Initiative (WHI) reports 4-6. The Million Women 
observational study(MWS)7 from the United Kingdom also implicated 
the role of additional progestin and prompted the comment that 
there is “…little advantage to using oestrogen-progestogen in 
preference to oestrogen-only HRT for women who still have a 
uterus”. This paper will review the data on the role of progestin in 
HRT, the merits of different regimens and types of progestin to help 
in answering the question. 
 
 
Endometrial hyperplasia and cancer 
1.Sequential HRT 
Endometrial cancer remains an important cause of morbidity and 
mortality among women worldwide, although the incidence is much 
higher in the developed world. One risk factor is a delayed or late 
menopause, so HRT which effectively prolongs the menopausal age 
could increase the risk. The ideal HRT regimen will relieve 
menopausal symptoms without increasing the risk of hormone 
dependant disease, but the possibility of causing endometrial or 
breast cancers dominate current prescribing practice. Unopposed 
estrogen is associated with a significant increased risk of irregular 
bleeding, endometrial hyperplasia and cancer. A Cochrane review of 
all the appropriate studies8 found that after 6 months of unopposed 
estrogen, the odds ratio(OR) of developing endometrial hyperplasia 
was 5.4 (95% confidence interval (CI) 1.4-20.9) and after 36 months 
was 16.0 (95%CI 9.3-27.5). Prolonged use of unopposed estrogen is 
associated with progression to endometrial cancer with relative risks 
(RR) upwards of 1.41,2 and increasing with duration to 15.03. 
Furthermore it is not widely recognised that the risk of endometrial 
cancer remains increased for many years after stopping unopposed 
estrogen9. Even after 15 years or more without therapy there is still a 
significantly increased RR of 5.8 (95% CI 2.0-17). To counteract this 
risk, progestins have been added to estrogen replacement therapy in 
a sequential regimen for usually 10-14 days in each cycle, with the 
intention of imitating the normal pre-menopausal ovarian cycle, and 
producing a regular and predictable withdrawal bleed, which can be 
beneficial for many women experiencing irregular peri-menopausal 
bleeding and menopausal symptoms. 
Estrogen causes endometrial proliferation by increasing the number 
of estrogen/progesterone receptors and also increasing the mitotic 
rate in the glandular cells of the endometrium. The administration of 
progestin during estrogen therapy causes a down-regulation of the 
receptors and induction of 17β-estradiol dehydrogenase, which 
converts estradiol to the less active estrone, thereby reducing the 
estrogenic stimulus10. The histological evidence of a progestin effect 
is a change from a proliferative to a secretory endometrium from 
which hyperplasia is less likely to develop. The effects of sequential 
regimens have been much studied and have confirmed that the 
progestin addition does reduce the incidence of endometrial 
hyperplasia and that this is greater with 12-13 days of progestin per 
cycle compared to fewer days11. However, with longer duration of 
HRT use the protective effect seems to diminish. One study of 1106 
women taking sequential therapy containing 10-12 days of progestin, 
for a mean of 3.29 years found a secretory endometrium in 47.5%, 
but complex hyperplasia in 5.3% and atypical hyperplasia in 0.7%12. 
This compares with the findings in peri- and post-menopausal 
women without symptoms of a 5.2% incidence of endometrial 
hyperplasia13. After three years of sequential HRT the PEPI trial14 
reported a 1.7% prevalence of hyperplasia compared to 0.8% on 
placebo and Weiderpass15 found that the RR of endometrial cancer 
with sequential therapy increased from 1.5 (95%CI 1.0-2.2) with less 
than five years use to 2.9 (95%CI 1.06-1.15) with more than five 
years use. 
As monthly sequential therapy results in a cyclical bleed, which is 
inconvenient for some women and may reduce compliance, 
attempts have been made to limit the frequency of bleeding by 
longer sequential cycles ranging from 3 to 6 months. However, David 
and colleagues16 demonstrated that simple hyperplasia develops 
after just three months of unopposed estrogen, so this has been 
generally considered to be the maximum interval for adding 
progestin. The Scandinavian Long Cycle Study Group17 compared 
monthly with three monthly sequential therapy and found that the 
incidence of endometrial pathology (simple, complex or atypical 
hyperplasia, or cancer) was significantly higher in the three monthly 
cycle group (P = 0.0003), with an annual incidence of 5.6% as 
compared to 1% in the monthly cycle group. They further confirmed 
that long-cycle therapy resulted in more irregular bleeding but no 
improved compliance. Conversely, another study from Finland found 
no increase in hyperplasia over 5 years using a combination of 
estradiol valerate 2mg and MPA 20mg18.  
All these data indicate that progestins will reduce the risk of 
endometrial; hyperplasia and cancer, but that the duration of 
progestin in each cycle is important and should be for at least 10 
days. Furthermore there may still be a risk with long term use of 
monthly sequential HRT and probably more so with long-cycle 
regimens. 
 
2. Continuous combined therapy 
The biochemical and morphological changes in the endometrium 
induced by progestin are maintained as long as the progestin is 
administered19. If this is continuous, the proliferative effect of 
estrogen will be prevented and the endometrium should become 
atrophic. This was the rationale for the introduction of continuous 
combined therapy (CCT)20, since without any cycle or a progestin 
phase, and with no tissue to be shed, there should not be any 
bleeding, whereas the benefits should be the same as for sequential 
therapy. Although the main aim of CCT is to avoid cyclical bleeding, 
all studies of CCT have found a high incidence of bleeds, particularly 
in the first three months, varying from 50-80%. This occurs more 
often in women who are within one year of the menopause rather 
than postmenopausal21,22. However, once the bleeding has subsided, 
amenorrhoea is usually maintained indefinitely. 
Many studies have confirmed that an atrophic endometrium is 
achieved with CCT in 90-100% of women, even after only 3 months 
of treatment with daily doses of progestin as low as 0.25mg/day 
norethisterone acetate or 2.5mg/day of medroxyprogesterone 
acetate (MPA). After one year of treatment with conjugated equine 
estrogens (CEE) 0.625mg/day and MPA 2.5 or 5.0mg/day, Woodruff 
and Pickar23 found endometrial hyperplasia without atypia in <1% of 
women, which is less than the background rate in postmenopausal 
women. The Cochrane review reported that endometrial hyperplasia 
may be less likely with CCT than a sequential regimen, in particular 
with long duration of therapy; OR 0.3 (95%CI 0.1-0.97)8. 
 In the UK a multicenter study reported on 751 women who had 
previously been taking sequential HRT and 445 untreated 
postmenopausal women (total 1196) who completed 9 months of 
CCT with estradiol 2mg/day and norethisterone acetate 1mg/day12. 
There were no cases of endometrial hyperplasia and the 
endometrium was atrophic in more than two thirds of the women. 
Furthermore, all the women with complex hyperplasia during their 
prior sequential HRT and who completed the study (n=42) reverted 
to normal endometrial patterns. Continuation of this study for 5 
years confirmed the protective effect of this CCT regimen in 387 
women, with >70% having an atrophic endometrium and the 
remainder having other normal histology and no hyperplasia or 
cancer24. These data indicate the protective effect of the continuous 
progestin of CCT regimens not only in preventing hyperplasia but 
also the correction of pre-existing hyperplasia. 
Assuming that endometrial carcinoma will usually develop from 
hyperplasia, the prevention of hyperplasia with CCT should also 
prevent cancer. A population-based control study in Sweden 
reported that with less than five years of CCT the observed risk of 
developing cancer was 0.8 (95%CI 0.5-1.3) and with more than five 
years use it was 0.2 (95%CI 0.1-0.8)15. The largest randomised 
controlled trial of HRT, the WHI study, reported that after CCT with 
CEE 0.625mg/day and MPA 2.5mg/day for a mean of 5.3 years in 
8506 women, there was no change in the risk of endometrial cancer 
compared to the placebo arm. The hazard ratio(HR) was 0.63 (95%CI 
0.47-1.47)25. However, the MWS reported that with last use of a CCT 
regimen the risk of endometrial cancer was significantly reduced, the 
relative risk being 0.71 (95%CI 0.56-0.90) p = 0.00526 (table 1). Since 
these studies were designed and partly as a result of their reporting 
and National Regulatory Authorities responses, there has been a 
move to the use of lower doses of estrogen and progestins than used 
in the WHI studies and ultra-low dose CCT regimens are now 
available. Estradiol 0.5 mg is the lowest dose that is effective in 
relieving vasomotor symptoms27 and combined with either 2.5mg 
dydrogesterone or 0.1mg norethisterone also has less stimulation of 
the endometrium and very acceptable amenorrhoea rates compared 
with higher dose regimens28-31.  
Progestins are added to HRT solely to protect the endometrium from 
the proliferative effects of estrogen, so it is logical to deliver the 
progestin directly to the endometrial cavity. An intrauterine system 
delivering levonorgestrel has been available for many years for the 
management of menorrhagia and contraception (Mirena®), but has 
also been used as part of CCT regimens and provides excellent 
endometrial protection32,33. 
Adherence with HRT 
Some side effects are experienced by most women taking HRT but in 
many they are mild and transient and with appropriate counselling 
should not affect continuation. However, reports of the rates of 
discontinuation of HRT vary widely and are dependent on many 
factors such as the indication for taking HRT, the quality of the initial 
consultation and patient information/discussion, patient 
expectation, type of HRT, side effects, anxiety about safety, 
especially breast cancer. The most frequent reasons given for 
discontinuation are bleeding and weight gain and pre-menstrual-type 
symptoms such as bloating, headaches and breast tenderness34,35. 
Many of these are less common in those who have had a 
hysterectomy and are taking unopposed estrogen, so they are 
attributable to the progestin component. Strategies to counter these 
problems require individualisation of treatment and include changing 
to a different type of progestin or using natural progesterone, 
reducing the dose or route of administration.  For the rare cases of 
severe progestin intolerance and who need estrogen for menopausal 
symptoms, unopposed estrogen may be given and the endometrium 
monitored by regular transvaginal ultrasound. When the 
endometrium becomes more than 5mm thick a course of progestin is 
given to arrest proliferation and cause endometrial shedding36. This 
management strategy requires good patient compliance and reliable 
ultrasound scanning. 
Hormones and the breast 
The differential effects of estrogens and progestins/progesterone on 
the breast have been the subject of considerable study and debate 
for many years, and especially since the WHI study reports. While 
progestins protect the endometrium from the proliferative effects of 
estrogen in postmenopausal women taking HRT, this is not replicated 
in the breast37. Indeed, during the menstrual cycle it is evident that 
peak proliferation of breast tissue occurs during the late luteal phase 
when natural progesterone levels are maximal, but also there is an 
increase in apoptosis at this time38. The WHI study has confirmed this 
differential effect with a lower incidence of invasive breast cancer 
after the use of unopposed CEE for a median of 5.9 years, HR 0.77 
(95%CI 0.62-0.95)39, whereas the combined CEE and MPA arm was 
associated with a non-significant trend towards an increased risk HR 
1.26 (adjusted 95%CI 0.83-1.92)4. But the media reporting of the 
initial paper of an increase in breast cancer of 26% implied a 
significant risk, and with banner headlines in newspapers across the 
world, a generation of women and doctors have remained mostly 
now too frightened to consider taking or prescribing HRT. In addition 
the comments from the authors that this was demonstrating a class 
effect of HRT implied that no HRT was safe. The subsequent report 
from the MWS of an even greater risk with all types of HRT and 
especially with combined estrogen and progestin regimens 
compounded the fears7. In contrast to endometrial cancer, the risk of 
breast cancer declines back to baseline within five years after 
cessation of HRT40. 
In countries outside North America, MPA is used much less than a 
wide range of other progestins with varying metabolic effects, 
though similar endometrial protection. The E3N is a prospective 
cohort initiated in France in 1990 to investigate the risk factors for 
cancer in women. In particular it has addressed breast cancer and 
associations with different types and regimens of HRT. During follow-
up (mean duration 8.1 postmenopausal years), 2354 cases of breast 
cancer occurred among 80,377 postmenopausal women. Compared 
with women who had never used HRT, women who used estrogen 
alone had 1.29-fold increased risk (95%CI 1.02-1.65). The association 
of combined estrogen and progestin regimens with breast cancer risk 
varied significantly according to the type of progestin. The RR was 
1.00 (95%CI 0.83-1.22) for estrogen-progesterone, 1.16 (95%CI 0.94-
1.43) for estrogen-dydrogesterone, and 1.69 (95%CI 1.50-1.91) for 
estrogen combined with other progestins (Table 2). The other 
progestins included – medrogestone, chlormadinone acetate, 
cyproterone acetate, promegestone, nomegestrol acetate, 
norethisterone acetate and MPA, but their associations with breast 
cancer risk did not differ significantly from each other41. These 
findings suggest that the choice of progestin in combined HRT 
regimens may be important regarding breast cancer risk and 
confirms that there is no class effect of HRT. It is therefore time that 
the WHI investigators stop referring to their data with CEE and MPA 
as estrogen and progestin and recognise the difference, as in the 
latest paper from the observational arm, reporting after a mean of 
11.3 years of combined therapy a HR of 1.55 (95%CI 1.41-1.70;  
P<0.001)42. 
The dose as well as type of progestin may also be important in 
contributing to the risk of breast cancer. New ultra-low dose 
combined regimens have no effect on endometrial thickness and one 
combination of estradiol 0.5mg with norethisterone 0.1mg did not 
cause any detectable change in breast density over 6 months43. It is 
unlikely ever to be tested in a large enough randomized study to 
identify the outcome for breast cancer. 
The intrauterine delivery of the progestin levonorgestrel results in 
lower circulating levels than with oral administration but a case-
control study has shown an increased risk of breast cancer when 
used alone or in combination with estradiol44,45. 
Conclusions 
The type and regimen of HRT should always be tailored to the 
individual woman, so the answer to the title question will depend on 
assessment of the risks and benefits of each strategy, weighing up 
the evidence and coming to a joint informed decision of the woman 
with her medical adviser. Hysterectomy rates globally may be 
decreasing with the wider use of endometrial ablative techniques, 
intrauterine progestin-releasing systems and effective medical 
managements, so the proportion of women reaching the menopause 
and potentially at risk of endometrial cancer may increase. It is for 
these women that the decision on the use of progestins with HRT is 
pertinent. The evidence presented above may be condensed in to 
the following points for either unopposed estrogen or the 
combination with a progestin: 
In favour of unopposed 
estrogen 
In favour of additional 
progestin 
Additional progestin associated 
with  greater risk of breast 
cancer 
Unopposed estrogen associated 
with significantly increased risk of 
endometrial hyperplasia and 
cancer 
Very small risk of breast cancer 
with unopposed estrogen 
Additional progestin can protect 
from endometrial hyperplasia and 
cancer  
Fewer symptomatic side-effects; 
no cyclical PMS-type symptoms 
Unopposed estrogen may cause 
irregular bleeding which can be 
controlled/prevented by 
progestins 
Risk of endometrial cancer much 
less over short duration of use 
Progesterone and dydrogesterone 
may not increase risk of breast 
cancer 
Easier administration Risk of endometrial cancer 
remains for many years after 
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Legends for tables: 
Table 1.  
Summary of relative risks (RR) and 95% confidence intervals (CI) for 
endometrial cancer with different durations of unopposed estrogen, 
sequential and continuous combined estrogen and progestin (CCT); 
data from Grady et al46; Wiederpass15; Anderson et al25; Beral et al26. 
 
Table 2 
 Risks for invasive breast cancer by type and duration of exposure, 
compared with HRT never-use. (From ref 41 with permission) 
[ aPY= person-years; b adjusted for covariates; c orally or vaginally administered 
promestriene or estriol; d Intramuscularly administered estrogen or 
progestogen, androgen, nasally administered progestogen, or tibolone; 
ewomen who did not use the same class of HRT throughout follow-up 













Type of HRT RR 95% CI 
Unopposed estrogen <1yr 1.4 1.0-1.8 
1-4 yrs 2.8 2.3-3.5 
5-9 yrs 5.9 4.7-7.5 
10+ yrs 9.5 7.4-12.3 
Sequential E + P < 5yrs 1.5 1.0-2.2 
>5yrs 2.9 1.8-4.6 
CCT (MWS) 0.7 0.6-0.9 
CCT (WHI) 5.3yrs 0.6 0.5-1.5 
CCT >5yrs 0.2 0.1-0.8 
 
 
 
 
 
 
 
 
 
 
Table 2. 
 
